Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs

See what CB Insights has to offer

Founded Year

1996

Stage

Acquired | Acquired

Total Raised

$246.64M

About Abgenix

Abgenix aims to deliver fully human monoclonal antibodies for a range of disease targets, several of which are currently in clinical trials. The company leverages its XenoMouse technology platform to support product development, while offering the platform to its strategic partners and licensing customers.

Abgenix Headquarter Location

6701 Kaiser Drive

Fremont, California, 94555,

United States

510-284-6500

Latest Abgenix News

Open Monoclonal Technology Announces OmniAb Alliance With Amgen

Jun 14, 2015

Amgen licenses AMG 714 to start-up Celimmune Dr. Roland Buelow, OMT founder and CEO, said, “Amgen was an early protein therapeutics leader and became one of a few companies with transgenic mouse platforms for human antibody discovery in 2005 when they acquired Abgenix and its XenoMouse®. With the license from OMT, Amgen further builds on this capability as it gains access to complementary platforms for development of fully human, mono- and bispecific antibodies without any target restrictions.” About Open Monoclonal Technology, Inc. Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for the generation of human therapeutic antibodies, naturally optimized human antibodies®, and the only company in the world with four transgenic animal platforms, jointly known as OmniAb™. OmniRat® is the industry’s first human monoclonal antibody technology based on rats. It has a complete immune system with a diverse antibody repertoire and generates antibodies with human idiotypes as well as wild-type animals make rat antibodies. OmniMouse® is a transgenic mouse that complements OmniRat and expands epitope coverage. OmniFlic™ is an engineered rat with a fixed light chain for development of bispecific, fully human antibodies. UniRat™ is the first transgenic rat generating fully human heavy chain-only antibodies and nanobodies for polyspecific applications. All four OmniAb™ platforms deliver human antibodies with high affinity, specificity, expression, solubility and stability. They use patented technology, have broad freedom to operate and are available worldwide for all targets and indications. Current partners include Amgen, Caltech, Celgene, Chugai, Genmab, Genentech, HanAll, Janssen, Merck KGaA, Pfizer, Roche, Symphogen, University of Nottingham and several undisclosed biotech and pharmaceutical companies. Animal hosting and OmniAb antibody discovery services are available via Antibody Solutions, Panoply Bio and Sage Labs in the US, Aldevron and Taconic Biosciences in Europe, and WuXi AppTec in China. For more information, please visit www.omtinc.net . View source version on businesswire.com: http://www.businesswire.com/news/home/20150614005086/en/ Open Monoclonal Technology, Inc.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Abgenix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Abgenix is included in 1 Expert Collection, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Abgenix Patents

Abgenix has filed 2 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/28/2005

8/7/2012

Monoclonal antibodies, Clusters of differentiation, Immunology, Immune system, Experimental cancer drugs

Grant

Application Date

9/28/2005

Grant Date

8/7/2012

Title

Related Topics

Monoclonal antibodies, Clusters of differentiation, Immunology, Immune system, Experimental cancer drugs

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.